Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on PHVS stock, giving a Buy rating today.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Schwartz has given his Buy rating due to a combination of factors including the positive topline data from Pharvaris’ RAPIDe-3 study. The study results showed that deucrictibant, an oral small-molecule antagonist of the bradykinin B2 receptor, demonstrated a median time to symptom relief of 1.28 hours, which is competitive with existing treatments. Additionally, all secondary efficacy endpoints achieved statistical significance, reinforcing the drug’s potential effectiveness.
Furthermore, the safety profile of deucrictibant was consistent with previous studies, showing no new safety signals. Pharvaris plans to submit a New Drug Application in the first half of 2026, with further data expected from the CHAPTER-3 study in the prophylaxis setting. The analyst also noted the strong market opportunity for HAE treatments, suggesting that the market can accommodate multiple players as it expands. As a result, the price target for Pharvaris has been increased to $38, reflecting confidence in the company’s future prospects.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.